Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes

David R Powell, Deon Doree, Sabrina Jeter-Jones, Zhi-Ming Ding, Brian Zambrowicz, Arthur Sands Lexicon Pharmaceuticals, The Woodlands, TX, USA Purpose: Oral agents are needed that improve glycemic control without increasing hypoglycemic events in patients with type 1 diabetes (T1D). Sotagliflozin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Powell DR, Doree D, Jeter-Jones S, Ding ZM, Zambrowicz B, Sands A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/1034519483334cc29f9be744afccfd80
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1034519483334cc29f9be744afccfd80
record_format	dspace
spelling	oai:doaj.org-article:1034519483334cc29f9be744afccfd802021-12-02T01:21:56ZSotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes1178-7007https://doaj.org/article/1034519483334cc29f9be744afccfd802015-02-01T00:00:00Zhttp://www.dovepress.com/sotagliflozin-improves-glycemic-control-in-nonobese-diabetes-prone-mic-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007 David R Powell, Deon Doree, Sabrina Jeter-Jones, Zhi-Ming Ding, Brian Zambrowicz, Arthur Sands Lexicon Pharmaceuticals, The Woodlands, TX, USA Purpose: Oral agents are needed that improve glycemic control without increasing hypoglycemic events in patients with type 1 diabetes (T1D). Sotagliflozin may meet this need, because this compound lowers blood glucose through the insulin-independent mechanisms of inhibiting kidney SGLT2 and intestinal SGLT1. We examined the effect of sotagliflozin on glycemic control and rate of hypoglycemia measurements in T1D mice maintained on a low daily insulin dose, and compared these results to those from mice maintained in better glycemic control with a higher daily insulin dose alone. Materials and methods: Nonobese diabetes-prone mice with cyclophosphamide-induced T1D were randomized to receive one of four daily treatments: 0.2 U insulin/vehicle, 0.05 U insulin/vehicle, 0.05 U insulin/2 mg/kg sotagliflozin or 0.05 U insulin/30 mg/kg sotagliflozin. Insulin was delivered subcutaneously by micro-osmotic pump; the day after pump implantation, mice received their first of 22 once-daily oral doses of sotagliflozin or vehicle. Glycemic control was monitored by measuring fed blood glucose and hemoglobin A1c levels. Results: Blood glucose levels decreased rapidly and comparably in the 0.05 U insulin/sotagliflozin-treated groups and the 0.2 U insulin/vehicle group compared to the 0.05 U insulin/vehicle group, which had significantly higher levels than the other three groups from day 2 through day 23. A1c levels were also significantly higher in the 0.05 U insulin/vehicle group compared to the other three groups on day 23. Importantly, the 0.2 U insulin/vehicle group had, out of 100 blood glucose measurements, 13 that were <70 mg/dL compared to one of 290 for the other three groups combined. Conclusion: Sotagliflozin significantly improved glycemic control, without increasing the rate of hypoglycemia measurements, in diabetic mice maintained on a low insulin dose. This sotagliflozin-mediated improvement in glycemic control was comparable to that achieved by raising the insulin dose alone, but was not accompanied by the increased rate of hypoglycemia measurements observed with the higher insulin dose. Keywords: insulin, glucose, hypoglycemia, hemoglobin A1cPowell DRDoree DJeter-Jones SDing ZMZambrowicz BSands ADove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2015, Iss default, Pp 121-127 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Powell DR Doree D Jeter-Jones S Ding ZM Zambrowicz B Sands A Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
description	David R Powell, Deon Doree, Sabrina Jeter-Jones, Zhi-Ming Ding, Brian Zambrowicz, Arthur Sands Lexicon Pharmaceuticals, The Woodlands, TX, USA Purpose: Oral agents are needed that improve glycemic control without increasing hypoglycemic events in patients with type 1 diabetes (T1D). Sotagliflozin may meet this need, because this compound lowers blood glucose through the insulin-independent mechanisms of inhibiting kidney SGLT2 and intestinal SGLT1. We examined the effect of sotagliflozin on glycemic control and rate of hypoglycemia measurements in T1D mice maintained on a low daily insulin dose, and compared these results to those from mice maintained in better glycemic control with a higher daily insulin dose alone. Materials and methods: Nonobese diabetes-prone mice with cyclophosphamide-induced T1D were randomized to receive one of four daily treatments: 0.2 U insulin/vehicle, 0.05 U insulin/vehicle, 0.05 U insulin/2 mg/kg sotagliflozin or 0.05 U insulin/30 mg/kg sotagliflozin. Insulin was delivered subcutaneously by micro-osmotic pump; the day after pump implantation, mice received their first of 22 once-daily oral doses of sotagliflozin or vehicle. Glycemic control was monitored by measuring fed blood glucose and hemoglobin A1c levels. Results: Blood glucose levels decreased rapidly and comparably in the 0.05 U insulin/sotagliflozin-treated groups and the 0.2 U insulin/vehicle group compared to the 0.05 U insulin/vehicle group, which had significantly higher levels than the other three groups from day 2 through day 23. A1c levels were also significantly higher in the 0.05 U insulin/vehicle group compared to the other three groups on day 23. Importantly, the 0.2 U insulin/vehicle group had, out of 100 blood glucose measurements, 13 that were <70 mg/dL compared to one of 290 for the other three groups combined. Conclusion: Sotagliflozin significantly improved glycemic control, without increasing the rate of hypoglycemia measurements, in diabetic mice maintained on a low insulin dose. This sotagliflozin-mediated improvement in glycemic control was comparable to that achieved by raising the insulin dose alone, but was not accompanied by the increased rate of hypoglycemia measurements observed with the higher insulin dose. Keywords: insulin, glucose, hypoglycemia, hemoglobin A1c
format	article
author	Powell DR Doree D Jeter-Jones S Ding ZM Zambrowicz B Sands A
author_facet	Powell DR Doree D Jeter-Jones S Ding ZM Zambrowicz B Sands A
author_sort	Powell DR
title	Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
title_short	Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
title_full	Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
title_fullStr	Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
title_full_unstemmed	Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
title_sort	sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/1034519483334cc29f9be744afccfd80
work_keys_str_mv	AT powelldr sotagliflozinimprovesglycemiccontrolinnonobesediabetespronemicewithtype1diabetes AT doreed sotagliflozinimprovesglycemiccontrolinnonobesediabetespronemicewithtype1diabetes AT jeterjoness sotagliflozinimprovesglycemiccontrolinnonobesediabetespronemicewithtype1diabetes AT dingzm sotagliflozinimprovesglycemiccontrolinnonobesediabetespronemicewithtype1diabetes AT zambrowiczb sotagliflozinimprovesglycemiccontrolinnonobesediabetespronemicewithtype1diabetes AT sandsa sotagliflozinimprovesglycemiccontrolinnonobesediabetespronemicewithtype1diabetes
_version_	1718403119549775872

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes

Ejemplares similares